FDA OFFICE OF INDUSTRY AND TRADE RELATIONS TO BE HEADED BY JACK MARTIN
Executive Summary
FDA OFFICE OF INDUSTRY AND TRADE RELATIONS TO BE HEADED BY JACK MARTIN, special assistant to the commissioner and former associate commissioner for public affairs under FDA Commissioner Frank Young. Other office staff will include Mary Ann Danello, currently special assistant to the commissioner for science, and public affairs staffer Elizabeth Wright. The formation of the office was announced by FDA Acting Commissioner Benson at the May 17 meeting of the FDA blue ribbon panel. FDA will send out letters next month to regulated industry, including individual companies as well as trade associations, announcing the formal establishment of the office and detailing the office's responsibilities. The Office of Industry and Trade Relations will be a source for the industry of information on FDA regulations, policy, and legislation, FDA noted. Currently there is no single source of such information at FDA. The office will also disseminate information from the industry to the commissioner and the centers. However, the office will not serve as ombudsman to companies, FDA said. The role of the office is not to field complaints or solve problems between FDA and companies, but to serve as an "out basket" of agency information, FDA remarked. FDA plans to send staff from the office to trade shows and association meetings to promote better relations with industry. In addition, the office will concentrate on developing better communications with small businesses and insuring that information on FDA policy is reaches them.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth